• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Health Res Policy Syst . Rapid method through routine data to evaluate real-world vaccine effectiveness against coronavirus disease 2019 (COVID-19)

tetano

Editor, Senior Moderator
Health Res Policy Syst


. 2022 Mar 9;20(1):29.
doi: 10.1186/s12961-022-00821-6.
Rapid method through routine data to evaluate real-world vaccine effectiveness against coronavirus disease 2019 (COVID-19) infection: lessons from Thailand


Natthaprang Nittayasoot[SUP] 1 [/SUP], Panithee Thammawijaya[SUP] 1 [/SUP], Piyanit Tharmaphornpilas[SUP] 1 [/SUP], Chalo Sansilapin[SUP] 1 [/SUP], Chuleeporn Jiraphongsa[SUP] 1 [/SUP], Rapeepong Suphanchaimat[SUP] 2 3 [/SUP]



Affiliations

Abstract

The objective of this article is to draw lessons from the Thai experience in estimating vaccine effectiveness (VE) for coronavirus disease 2019 (COVID-19) based on routine service data. We found that a matched case-control design, using probability-based controls representing the varying vaccine coverage across the population over time, yielded a valid result for VE assessment. The proposed design has an advantage in its applicability drawing from the routine data monitoring system. Future studies that exercise other designs, such as test-negative and cohort studies, are recommended in order to compare and contrast the findings across different designs. To implement a continuous monitoring system on VE, the integration of data from different sources is needed. This requires long-term investment in the data monitoring system for the entire healthcare system.

Keywords: Case–control; Coronavirus disease 2019; Thailand; Vaccine effectiveness.
 
Back
Top Bottom